

CCL3L1 Antibody (internal region)
Peptide-affinity purified goat antibody
Catalog # AF2862a**Specification**

CCL3L1 Antibody (internal region) - Product Information

Application	E
Primary Accession	P16619
Other Accession	NP_066286.1 , 6349
Predicted	Human
Host	Goat
Clonality	Polyclonal
Concentration	0.5 mg/ml
Isotype	IgG
Calculated MW	10161

CCL3L1 Antibody (internal region) - Additional Information**Gene ID** 414062;6349**Other Names**

C-C motif chemokine 3-like 1, G0/G1 switch regulatory protein 19-2, LD78-beta(1-70), PAT 464.2, Small-inducible cytokine A3-like 1, Tonsillar lymphocyte LD78 beta protein, LD78-beta(3-70), LD78-beta(5-70), CCL3L1, D17S1718, G0S19-2, SCYA3L1

Dilution

E~~N/A

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

CCL3L1 Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures.

CCL3L1 Antibody (internal region) - Protein Information**Name** CCL3L1**Synonyms** D17S1718, G0S19-2, SCYA3L1**Function**

Chemotactic for lymphocytes and monocytes. Is a ligand for CCR1, CCR3 and CCR5. Is an inhibitor

of HIV-1-infection. The processed form LD78-beta(3-70) shows a 20-fold to 30-fold higher chemotactic activity and is a very potent inhibitor of HIV-1-infection. LD78- beta(3-70) is also a ligand for CCR1, CCR3 and CCR5.

Cellular Location

Secreted.

CCL3L1 Antibody (internal region) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

CCL3L1 Antibody (internal region) - Images**CCL3L1 Antibody (internal region) - References**

Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. McKinney C, Merriman ME, Chapman PT, Gow PJ, Harrison AA, Highton J, Jones PB.

McLean L, O'Donnell JL, Pokorny V, Spellerberg M, Stamp LK, Willis J, Steer S, Merriman TR. Ann Rheum Dis. 2008 Mar;67(3):409-13. PMID: 17604289